Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

NCT05656248 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Myeloid Neoplasm

Interventions

DRUG: CPX-351
DRUG: MHA
PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor

St. Jude Children's Research Hospital

Collaborators

[object Object]